Last update 19 Jun 2024

STSA-1002

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
STSA 1002, STSA-1002
Target
C5a
Mechanism
C5a inhibitors(complement C5a inhibitors)
Therapeutic Areas
Respiratory DiseasesImmune System DiseasesCardiovascular Diseases+ [1]
Active Indication
Respiratory Distress Syndrome, AdultAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Inactive Indication
COVID-19
Originator Organization
Staidson (Beijing) Biopharmaceuticals Co., Ltd.Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Active Organization
Staidson (Beijing) Biopharmaceuticals Co., Ltd.Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-

Related

7
Clinical Trials associated with STSA-1002
NCT06038916 / RecruitingPhase 1/2
Phase Ib/II Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
CTR20232868 / RecruitingPhase 1/2
随机、双盲、安慰剂对照评价STSA-1002注射液在急性呼吸窘迫综合征患者中的安全性及初步疗效的Ib/II期临床研究
[Translation] A randomized, double-blind, placebo-controlled Phase Ib/II clinical study to evaluate the safety and preliminary efficacy of STSA-1002 injection in patients with acute respiratory distress syndrome
NCT05702983 / CompletedPhase 1
An Open-label, Single-ascending Dose, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002 Subcutaneous Injection in Healthy Subjects
100 Clinical Results associated with STSA-1002
Login to view more data
100 Translational Medicine associated with STSA-1002
Login to view more data
100 Patents (Medical) associated with STSA-1002
Login to view more data
100 Deals associated with STSA-1002
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Respiratory Distress Syndrome, AdultPhase 2
CN
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
09 Dec 2023
Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisPhase 1
US
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
31 Jan 2023
COVID-19Phase 1
US
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
22 Aug 2022
COVID-19Phase 1
CN
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
22 Aug 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free